Considerable Absenteeism Costs for Chronic Disease, Risk Factors

Share this content:
Considerable Absenteeism Costs for Chronic Disease, Risk Factors
Considerable Absenteeism Costs for Chronic Disease, Risk Factors

WEDNESDAY, Oct. 19, 2016 (HealthDay News) -- Considerable costs are associated with absenteeism related to chronic diseases and health risk factors, according to a study published in the Oct. 6 issue of the U.S. Centers for Disease Control and Prevention's Preventing Chronic Disease.

Garrett R. Beeler Asay, Ph.D., from the CDC in Atlanta, and colleagues examined the correlation between employee absenteeism and five conditions using data from the MarketScan Health Risk Assessment and the Medical Expenditure Panel Survey (MEPS). Excess absenteeism was estimated for those who reported having a risk factor (smoking, physical inactivity, and obesity) or a chronic condition (hypertension and diabetes).

The researchers found that depending on the risk factor or chronic disease, absenteeism estimates varied from one to two days per individual per year. Disease- and risk-factor-specific estimates were similar in MEPS and MarketScan, except for the physical inactivity and obesity estimates. There was an increase in absenteeism with the number of risks factors or diseases reported. Each risk factor or disease correlated with annual absenteeism costs in excess of $2 billion nationally. Per employee per year, the costs of absenteeism varied from $16 to $81 for small employers and from $17 to $286 for large employers.

"Absenteeism costs associated with chronic diseases and health risk factors can be substantial," the authors write. "Employers may incur these costs through lower productivity, and employees could incur costs through lower wages."

Full Text

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters


More in Home

FDA Approves First Drug for Rare Form of Rickets

FDA Approves First Drug for Rare Form of ...

Crysvita approved for adults and children ages 1 year and older with x-linked hypophosphatemia

High FGF-23 Linked to Recurrent Cardiac Events After ACS

High FGF-23 Linked to Recurrent Cardiac Events After ...

FGF-23 in top quartile independently linked to greater risk of CV death, heart failure hospitalization

Medical Cannabis Not Recommended for Sleep Apnea

Medical Cannabis Not Recommended for Sleep Apnea

American Academy of Sleep Medicine says evidence insufficient to recommend cannabis for apnea

is free, fast, and customized just for you!

Already a member?

Sign In Now »